Pulse Biosciences (NASDAQ:PLSE) Trading Down 2.2% – Time to Sell?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price dropped 2.2% on Thursday . The company traded as low as $17.75 and last traded at $17.92. Approximately 39,761 shares traded hands during trading, a decline of 80% from the average daily volume of 199,232 shares. The stock had previously closed at $18.33.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research report on Tuesday.

Pulse Biosciences Stock Down 3.8 %

The stock has a 50 day simple moving average of $18.02 and a 200 day simple moving average of $16.77.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter last year, the business posted ($0.19) earnings per share.

Insider Buying and Selling

In other Pulse Biosciences news, Director Robert W. Duggan acquired 56,054 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the transaction, the director now owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in shares of Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after buying an additional 9,639 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the period. Quest Partners LLC bought a new stake in Pulse Biosciences during the second quarter worth approximately $91,000. Creative Planning lifted its position in Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Pulse Biosciences by 193.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after purchasing an additional 97,565 shares in the last quarter. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.